Fig. 2

Histopathological response and risk of recurrence according to neoadjuvant chemotherapy and RBM3 expression. a The proportion of patients with pathological downstaging of the primary tumour (pT0, Ta, CIS) as well as pathological non-invasive downstaging (≤pTa, CIS, N0) in the entire cohort and according to RBM3 expression. Kaplan-Meier estimates of b 5-year overall survival (OS), c 5-year cancer-specific survival (CSS) and d 3- and 5-year time to recurrence (TTR) after diagnosis stratified according to dichotomous RBM3 expression in TURB specimens and neoadjuvant chemotherapy. P-values are derived from log-rank test for pairwise comparison, with high RBM3/No NAC as the reference group (ref). NoE, number of events. e Forest plot illustrating hazard ratio with 95% confidence interval (CI) and p-values (p) from uni- and multivariable Cox proportional hazards analysis of 5-year OS, 5-year CSS and 3- and 5-year TTR, respectively. Multivariable model adjusted for age at diagnosis (continuous), T-stage at cystectomy, N-stage, neoadjuvant, and adjuvant chemotherapy. p_int: p-value for interaction derived from univariable and multivariable Cox regression analysis of OS, CSS and TTR, respectively, which included a term of interaction by multiplication of NAC status (±) and the binary covariate of RBM3 expression (low/high)